RenovoRx Announces Pricing Of Public Offering Of About 11.52 Million Shares At $1.05/shr
RenovoRx Inc. (RNXT) announced the pricing of a firm commitment, underwritten public offering of about 11.52 million shares of its
RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing
Neuronetics announces public stock offering
MALVERN, Pa. - Neuronetics , Inc. (NASDAQ: NASDAQ:STIM), a global leader in neuroscience with a market capitalization of $197 million, has launched an underwritten public offering of its common stock,
Mustang Bio Announces Pricing of $8 Million Public Offering
Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers,
Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering
Glucot (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the pricing of a “best efforts” public offering of approximately 2.
Volcon, Inc. Announces Pricing of $12.0 Million Underwritten Public Offering
Volcon, Inc. (NASDAQ:VLCN) (the “Company”), the first all-electric, off-road powersports company, today announced the pricing of a firm commitment underwritten public offering with gross proceeds to the
Volcon, Inc. Announces Launch of Proposed Public Offering
Volcon, Inc. (Nasdaq:VLCN) (the “Company”), the first all-electric, off-road powersports company, today announced that it has commenced a public offering to offer and sell securities, including shares of
Mustang Bio Prices Public Offering Of 2.65 Mln At $3.01/shr; Stock Down In Pre-market
Mustang Bio, Inc. (MBIO), a clinical-stage biopharmaceutical company, Thursday announced the pricing of a public offering of 2.65
Mustang Bio sets terms for $8M public offering
WORCESTER, Mass. - Mustang Bio , Inc. (NASDAQ:MBIO), a biopharmaceutical company engaged in the development of cell therapies for cancer treatment, has announced the pricing of a public offering expected to raise approximately $8 million.
RenovoRx launches public stock offering
MOUNTAIN VIEW, Calif. - RenovoRx , Inc. (NASDAQ:RNXT), a $35.7 million market cap developer of targeted oncology therapies, has initiated an underwritten public offering of its common stock and ...
Nasdaq9d
Akero Therapeutics Announces Pricing of Upsized Public Offering for $350 Million
Akero Therapeutics announced a public offering of over 5.3 million shares at $48 each, aiming for $350 million in proceeds. Akero Therapeutics, Inc. has announced a public offering of 5,333,420 ...
Morningstar10d
Akero Therapeutics Announces Proposed Public Offering of Common Stock
In addition, Akero intends to grant the underwriters a 30-day option to purchase up to an additional $45.0 million of shares of its common stock at the public offering price, less underwriting ...